Nivolumab Recommended for EU Approval in Head and Neck Cancer

March 24, 2017 – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck (SCCHN) following progression on platinum-based therapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor. The approval is based on the CheckMate-141 study, in which the median overall survival (OS) with nivolumab was … (leggi tutto)